Oncology Times:
doi: 10.1097/01.COT.0000289785.82599.63
Protocol Alert

PROTOCOL ALERT

Free Access
Article Outline
Collapse Box

Author Information

The following is a partial list of new clinical trials recently added to the NCI's Physician Data Query (PDQ) database, accessible online at www.cancer.gov (Click on “Clinical Trials”).

Back to Top | Article Outline

Lung Cancer

UCLA-0408078-01, AMGEN-20040153, NCT00094835

Phase I Study of AMG 706 in Combination With Paclitaxel and Carboplatin and/or Panitumumab in Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Age: 18 and over

Sponsor: NCI, Pharmaceutical / Industry

STUDY LEAD ORGANIZATION

Jonsson Comprehensive Cancer Center, UCLA

Karen Reckamp, MD, Protocol chair; Ph: 310-825-5788

CALGB-30307

Phase II Study of Sorafenib in Patients With Malignant Mesothelioma

Age: 18 and over

Sponsor: NCI

STUDY LEAD ORGANIZATION

Cancer and Leukemia Group B

Pasi Janne, MD, PhD, Protocol chair; Ph: 617-632-6076; Email: pjanne@partners.org

Back to Top | Article Outline

Prostate Cancer

NLG0103, NCT00105053

Vaccine Treatment for Hormone Refractory Prostate Cancer

Age: 19 and over

Sponsor: Pharmaceutical / Industry

STUDY LEAD ORGANIZATION

NewLink Genetics Corporation

Kyung Hee Chang, MD, PhD; Ph: 402-559-4436; kchang@unmc.edu

Karen Olechnowicz; Ph: 402-559-4627

KOS-202/NO18401, NCT00104130

Study of KOS-862 in Metastatic Prostate Cancer

Age: 18 and over

Sponsor: Pharmaceutical / Industry

STUDY LEAD ORGANIZATION

Kosan Biosciences

Inc. Kosan Biosciences; Ph: 1-800-605-6726

UCLA-0407043-01, ZENECA-4054IL/0006, ZENECA-D4320C00006, NCT00090363

Phase II Randomized Study of ZD4054 in Patients With Hormone-Refractory Prostate Cancer and Bone Metastases

Age: 18 and over

Sponsor: NCI, Pharmaceutical / Industry

STUDY LEAD ORGANIZATION

Jonsson Comprehensive Cancer Center, UCLA

Steven Wong, MD, Protocol chair; Ph: 310-206-8221, Email: sgwong@ucla.edu

Back to Top | Article Outline

Skin Cancer

UCLA-0408080-01, IDM-DC-MEL-202

Phase II Study of Vaccine Therapy Comprising Autologous Dendritic Cells Pulsed With Allogeneic Melanoma Tumor Cell Lysates (IDD-3) in Patients With Unresected Stage IIIB or IIIC or Stage IV Melanoma

Age: 18 and over

Sponsor: NCI, Pharmaceutical / Industry

STUDY LEAD ORGANIZATION

Jonsson Comprehensive Cancer Center, UCLA

Antoni Ribas, MD, Protocol chair; Ph: 310-206-3928, Email: aribas@mednet.ucla.edu

Back to Top | Article Outline

Solid Tumors

SPD758-109, NCT00104286

Study of Troxatyl Administered by Continuous Infusion to Subjects with Solid Tumors

Age: 18 and over

Sponsor: Pharmaceutical / Industry

STUDY LEAD ORGANIZATION

Structural Genomix

Baltimore: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Dawn Young; Ph: 410-614-5948

XL880-001, NCT00105924

Study of XL880 in Adults with Solid Tumors

Age: 18 and over

Sponsor: Pharmaceutical / Industry

STUDY LEAD ORGANIZATION

Exelixis, Incorporated

S. Michael Imperiale, MD, Study Director

Cindy Mahn; Ph: 910-772-6824; Email: cynthia.mahn@wilm.ppdi.com

202-01, NCT00105170

Safety and Tolerability of hCBE-11 in Subjects with Advanced Solid Tumors

Age: 18 and over

Sponsor: Pharmaceutical / Industry

STUDY LEAD ORGANIZATION

Biogen Idec

Scottsdale and Tucson: America Morris; Email: america.morris@biogenidec.com

Philadelphia: Roger B Cohen, MD; Ph: 215 214-1676; Email: Roger.Cohen@fcc.edu

XL999-001, NCT00104117

Study of XL999 in Adults with Solid Tumors

Age: 18 and over

Sponsor: Pharmaceutical / Industry

STUDY LEAD ORGANIZATION

Exelixis, Incorporated

Harold Keer, MD, PhD, Study Director

Cindy Mahn; Ph: 910-772-6824; Email: cynthia.mahn@wilm.ppdi.com

2005_004, NCT00104364

A Targeted Cytotoxic Investigational Agent Given to Patients with Advanced Solid Tumors

Age: 18 and over

Sponsor: Pharmaceutical / Industry

STUDY LEAD ORGANIZATION

Merck and Company, Incorporated

Call for Information; Ph: 1-888-577-8839

COG-ADVL0419

Phase I Study of Valproic Acid in Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors

Age: 2 to 21

Sponsor: NCI

STUDY LEAD ORGANIZATION

Children's Oncology Group

Jack Su, MD, Protocol chair

Ph: 832-822-4306

Heidi Russell, MD, Protocol co-chair; Ph: 832-822-4200; Email: hmrussel@txccc.org

Back to Top | Article Outline

Miscellaneous/Other

050093, NCT00103688

Effects of Pet Therapy on Pain in Cancer Patients

Age: 18 and over

Sponsor: Other

STUDY LEAD ORGANIZATION

NIH - Warren Grant Magnuson Clinical Center

Patient Recruitment and Public Liaison Office; Ph: 1-800-411-1222; Email: prpl@mail.cc.nih.gov; TTY: Ph: 1-866-411-1010

20040114, NCT00104650

Study of AMG 162 in Subjects with Advanced Cancer Currently Being Treated with Intravenous (IV) Bisphosphonates

Age: 18 and over

Sponsor: Pharmaceutical / Industry

STUDY LEAD ORGANIZATION

Amgen, Incorporated

Amgen Call Center Ph: 866-572-6436

2005_005, NCT00104351

A VX-680 (an Aurora Kinase Inhibitor) Study in Patients with Advanced Cancer

Age: 18 and over

Sponsor: Pharmaceutical / Industry

STUDY LEAD ORGANIZATION

Merck and Company, Incorporated

Call for Information; Ph: 1-888-577-8839

U10-04-02-007, NCT00101621

Pilot Study to Evaluate the Safety and Analgesic Activity of M40403 Co-Administered with an Opioid Agent for Cancer Pain

Phase II

Age Range: 18 and over

Sponsor: Pharmaceutical/Industry

STUDY LEAD ORGANIZATION

Metaphore Pharmaceuticals: clinicaltrials@metaphore.com

Carla Tabussi: 201–947-7707; ctabussi@metphore.com

20040206, NCT00101907

Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Subjects with Advanced Cancer

Phase I

Age Range: 18 and over

Sponsor: Pharmaceutical / Industry

STUDY LEAD ORGANIZATION

Amgen Call Center: 866–572-6436

LErafAON-ETU-104, NCT00100672

Phase I Study to Determine the Maximum Tolerated Dose of LErafAON in Patients with Advanced Cancer

Age Range: 18 and over

Sponsor: Pharmaceutical/Industry

STUDY LEAD ORGANIZATION

NeoPharm

Kristen Parker: 847–295-8678; kparker@neophrm.com

UCSF-H28355-23383-01, UCSF-03202, NCT00103155

Phase I Pilot Study of Radiofrequency Ablation in Patients with Low-Risk Papillary Thyroid Cancer Undergoing Thyroidectomy

Age Range: Over 21

Sponsor: NCI

STUDY LEAD ORGANIZATION

UCSF Comprehensive Cancer Center

Electron Kebebew, MD, Protocol chair: 415–885-3617; 800-888-8664; kebebewe@surgery.ucsf.edu

© 2005 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share